US Patent Issued to Xilio Development on Oct. 7 for "Anti-CTLA4 antibodies and methods of use thereof" (Massachusetts Inventor)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,142, issued on Oct. 7, was assigned to Xilio Development Inc. (Waltham, Mass.).

"Anti-CTLA4 antibodies and methods of use thereof" was invented by Margaret Karow (Waltham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) and their use in treating and preventing cancer, as well as compositions and kits comprising the anti-CTLA4 binding proteins."

The patent was filed on Dec. 26, 2019, under Application No. 17/417,244.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Pa...